A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
| カタログ番号 | 製品名 | ||
|---|---|---|---|
| T39595 | Disitamab vedotin | Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated ... | |
| T25593 | Labetuzumab govitecan | Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer. | |
| T36646 | Trastuzumab deruxtecan | Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of... | |
| T38951 | Isatuximab | Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38 , a protein highly expressed on hematological malignant cells, inclu... | |
| T36647 | Trastuzumab emtansine | Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab wit... | |
| T12706 | Reslizumab | Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. | |
| T9923 | Nimotuzumab | Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR). | |
| T27970 | Mabuterol free base | Mabuterol is a selective agonist of β2 adrenoreceptor with no beta 1-stimulation. Mabuterol inhibited the positive inotropic effect of isoprenaline at 10(-7) g/m... | |
| T9931 | Meplazumab | meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia. | |
| T10497 | Benralizumab | Benralizumab (MEDI-563) is an IL-5Rα-directed cytolytic monoclonal antibody that induces rapid, direct and nearly complete depletion of eosinophils via enhanced ... | |
| T9924 | Obinutuzumab | Obinutuzumab GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma. | |
| T13666 | Dupilumab | Dupilumab (RegN-668) can inhibit IL-4 and IL-13 signaling pathways and significantly improve moderate to severe atopic dermatitis.It is a human monoclonal antibo... | |
| T38362 | Guselkumab | Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of ... | |
| T39730 | Datopotamab deruxtecan | Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) . Datopotamab deruxtecan has a ... | |
| T39057 | Rozanolixizumab | Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing path... | |
| T37535 | Camrelizumab | Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhib... | |
| T11126 | Durvalumab | Durvalumab is an anti-PD-L1 monoclonal antibody, humanized.Durvalumab completely blocked the binding of PD-L1 to PD-1 and CD80, and the IC50s were 0.1 and 0.04 n... | |
| T38105 | Ixekizumab | Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL... | |
| T9922 | Matuzumab | Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in ... | |
| T9927 | Panitumumab | Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR). | |
| T9928 | Ranibizumab | Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A | |
| T9925 | Ofatumumab | Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation | |
| T9914 | Vedolizumab | Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of Crohn's disease and ulcerative colitis. | |
| T9962 | Mepolizumab | Mepolizumab is a humanized monoclonal antibody neutralizing IL-5. Mepolizumab can be used in studies about severe eosinophilic asthma and eosinophilic granulomat... | |
| T9904 | Bevacizumab | Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibito... | |
| T9909 | Pertuzumab | Pertuzumab anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to... | |
| T9906 | Ipilimumab | Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibito... | |
| T9916 | Alirocumab | Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture. | |
| T9908 | Pembrolizumab | Pembrolizumab is a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind... | |
| T9926 | Omalizumab | Omalizumab is a recombinant humanized monoclonal antibody against human immunoglobulin E IgE) | |
| T9920 | Evolocumab | Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9). | |
| T9915 | Eculizumab | Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5 | |
| T9903 | Avelumab | Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. Avelumab shows potential antibody-dependent cell-mediated cytotoxicity. | |
| T9918 | Daratumumab | Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells. | |
| T9901 | Adalimumab | Adalimumab anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha. | |
| T9907 | Nivolumab | Nivolumab anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell ... | |
| T9911 | Tocilizumab | Tocilizumab anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor | |
| T12177 | Natalizumab | Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. | |
| T9930 | Secukinumab |
Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the trea... |
|
| T9929 | Ramucirumab | Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. | |
| T9921 | Infliximab | Infliximab is a humanized antibody against tumor necrosis factor α TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis. | |
| T9913 | Ustekinumab | Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody. | |
| T9912 | Trastuzumab | Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER... | |
| T9919 | Alemtuzumab | Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes. | |
| T9905 | Cetuximab | Cetuximab (anti-EGFR) a novel molecular-targeted agentis an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EG... | |
| T9902 | Atezolizumab | Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD... | |
| T9910 | Rituximab | Rituximab anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM. |
